Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S26-S35 , March 2004

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ A preliminary report of these findings was presented at the Annual Meeting of the American Academy of Ophthalmology, November 11–14, 2001; New Orleans, Louisiana. The study was managed by Ophthalmic Research Associates, a contract research organization, in association with Allergan, Inc. This study was sponsored by Allergan, Inc., Irvine, California.T. Walters, H. DuBiner, S. Carpenter and the investigators in the Bimatoprost Circadian IOP Study Group have no proprietary interests in the study medications or in Allergan, Inc. B. Khan and A. VanDenburgh are employees of Allergan, Inc.

PII: S0039-6257(03)00192-9

doi: 10.1016/j.survophthal.2003.12.017

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S26-S35 , March 2004

Article Tools

* Image Usage & Resolution